中国危重病急救医学
中國危重病急救醫學
중국위중병급구의학
CHINESE CRITICAL CARE MEDICINE
2010年
5期
279-281
,共3页
贺志飚%金丽艳%柴湘平%张东山
賀誌飚%金麗豔%柴湘平%張東山
하지표%금려염%시상평%장동산
丹参多酚酸盐%肺疾病,阻塞性,慢性%急性加重期%血小板%血浆膜糖蛋白140%CD62P%CD61%内皮细胞
丹參多酚痠鹽%肺疾病,阻塞性,慢性%急性加重期%血小闆%血漿膜糖蛋白140%CD62P%CD61%內皮細胞
단삼다분산염%폐질병,조새성,만성%급성가중기%혈소판%혈장막당단백140%CD62P%CD61%내피세포
Depsides salts from salvia miltiorrhiza%Chronic obstructive pulmonary disease%Acute exacerbation stage%Platelet%Plasma membrane glyeoprotein 140%CD62P%CD61%Endothelioeyte
目的 探讨丹参多酚酸盐(DSM)对重度慢性阻塞性肺疾病急性加重期(AECOPD)患者血小板和血管内皮细胞功能变化的影响.方法 将40例中重度AECOPD患者按随机数字表法分为常规治疗组、DSM组,每组20例;并选择同期20例健康者作为健康对照组.两组常规治疗相同;DSM组每日加用DSM0.2 g静脉滴注,连用2周.应用酶联免疫吸附法检测血浆膜糖蛋白140(GMP140)和血管性血友病因子(vMF),应用流式细胞术检测血小板膜糖蛋白P-选择素/血小板质膜蛋白(CD62P/CD61)表达双阳性血小板百分率.结果 两个治疗组治疗前GMP140C常规治疗组(17.51±2.75)μg/L,DSM组(16.94±2.57)μg/L]、vMF水平(常规治疗组(13.64±2.37)μg/L,DSM组(14.14±2.17)μg/L]及CD62P/CD61双阳性血小板百分率[常规治疗组(20.24±2.64)%,DSM组(19.54±2.69)%]较健康对照组[(9.25±1.80)μg/L、(6.13±1.17)μg/L、(11.21±1.11)%]均显著上升(均P<0.01);治疗后两组GMP140、vMF水平及CD62P/CD61双阳性血小板百分率显著降低,且DSM组的下降幅度[GMP140(3.91±0.57)μg/L,vWF(3.86±0.71)μg/L,CD62P/CD61(3.69±0.62)%]较常规治疗组[GMP140(2.30±0.33)μg/L,vWF(2.72±0.45)μg/L,CD62P/CD61(2.24±0.45)%]更为显著(均P<0.01),但是均高于正常水平.结论 DSM有显著抑制血管内皮细胞和血小板活化的作用,可预防血栓性疾病.
目的 探討丹參多酚痠鹽(DSM)對重度慢性阻塞性肺疾病急性加重期(AECOPD)患者血小闆和血管內皮細胞功能變化的影響.方法 將40例中重度AECOPD患者按隨機數字錶法分為常規治療組、DSM組,每組20例;併選擇同期20例健康者作為健康對照組.兩組常規治療相同;DSM組每日加用DSM0.2 g靜脈滴註,連用2週.應用酶聯免疫吸附法檢測血漿膜糖蛋白140(GMP140)和血管性血友病因子(vMF),應用流式細胞術檢測血小闆膜糖蛋白P-選擇素/血小闆質膜蛋白(CD62P/CD61)錶達雙暘性血小闆百分率.結果 兩箇治療組治療前GMP140C常規治療組(17.51±2.75)μg/L,DSM組(16.94±2.57)μg/L]、vMF水平(常規治療組(13.64±2.37)μg/L,DSM組(14.14±2.17)μg/L]及CD62P/CD61雙暘性血小闆百分率[常規治療組(20.24±2.64)%,DSM組(19.54±2.69)%]較健康對照組[(9.25±1.80)μg/L、(6.13±1.17)μg/L、(11.21±1.11)%]均顯著上升(均P<0.01);治療後兩組GMP140、vMF水平及CD62P/CD61雙暘性血小闆百分率顯著降低,且DSM組的下降幅度[GMP140(3.91±0.57)μg/L,vWF(3.86±0.71)μg/L,CD62P/CD61(3.69±0.62)%]較常規治療組[GMP140(2.30±0.33)μg/L,vWF(2.72±0.45)μg/L,CD62P/CD61(2.24±0.45)%]更為顯著(均P<0.01),但是均高于正常水平.結論 DSM有顯著抑製血管內皮細胞和血小闆活化的作用,可預防血栓性疾病.
목적 탐토단삼다분산염(DSM)대중도만성조새성폐질병급성가중기(AECOPD)환자혈소판화혈관내피세포공능변화적영향.방법 장40례중중도AECOPD환자안수궤수자표법분위상규치료조、DSM조,매조20례;병선택동기20례건강자작위건강대조조.량조상규치료상동;DSM조매일가용DSM0.2 g정맥적주,련용2주.응용매련면역흡부법검측혈장막당단백140(GMP140)화혈관성혈우병인자(vMF),응용류식세포술검측혈소판막당단백P-선택소/혈소판질막단백(CD62P/CD61)표체쌍양성혈소판백분솔.결과 량개치료조치료전GMP140C상규치료조(17.51±2.75)μg/L,DSM조(16.94±2.57)μg/L]、vMF수평(상규치료조(13.64±2.37)μg/L,DSM조(14.14±2.17)μg/L]급CD62P/CD61쌍양성혈소판백분솔[상규치료조(20.24±2.64)%,DSM조(19.54±2.69)%]교건강대조조[(9.25±1.80)μg/L、(6.13±1.17)μg/L、(11.21±1.11)%]균현저상승(균P<0.01);치료후량조GMP140、vMF수평급CD62P/CD61쌍양성혈소판백분솔현저강저,차DSM조적하강폭도[GMP140(3.91±0.57)μg/L,vWF(3.86±0.71)μg/L,CD62P/CD61(3.69±0.62)%]교상규치료조[GMP140(2.30±0.33)μg/L,vWF(2.72±0.45)μg/L,CD62P/CD61(2.24±0.45)%]경위현저(균P<0.01),단시균고우정상수평.결론 DSM유현저억제혈관내피세포화혈소판활화적작용,가예방혈전성질병.
Objective To investigate the influence of depsides salts from salvia miltiorrhiza (DSM) on the functions of platelet and vascular endothelial cell in severe chronic obstructive pulmonary diseases(COPD) patients with acute exacerbation.Methods Forty patients with severe COPD in acute exacerbation stage were randomly divided into two groups: conventional treatment (CT) group and DSM treatment(DSM) group, each consisting of 20 cases, and 20 healthy adults served as control group.All COPD patients were given conventional treatment, while for the patients in DSM group 0.2 g depsides DSM was given through intravenous drip everyday in addition for 2 weeks.The levels of the plasma platelet membrane glycoprotein 140 (GMP140) and yon Willebrand factor (vMF) in the blood samples were determined with enzyme linked immunosorbent assay (ELISA) and the level of CD62P/CD61 with flow eytometry (FCM).Results The level of GMP140 [CT group: (17.51±2.75)μg/L, DSM group: (16.94±2.57)μg/L], vMF[CT group: (13.64 ± 2.37)μg/L, DSM group: (14.14±2.17) μg/L] and CD62P/CD61 [CT group:(20.24±2.64)%, DSM group.(19.54±2.69)%] were elevated significantly in severe COPD patients with acute exacerbation compared to the control group before treatment [(11.21± 1.11)%, (9.25± 1.80) μg/L,(6.13±1.17) μg/L, all P<0.01].After intervention, the levels of the above three indexes in both treatment groups were significantly decreased, and the decrease in DSM group (GMP140: (3.91 ±0.57)μg/L, vWF: (3.86±0.71)μg/L, CD62P/CD61.(3.69±0.62)%] was more prominent than the CT group [GMP140: (2.30±0.33) μg/L, vWF: (2.72±0.45) μg/L, CD62P/CD61 : (2.24±0.45)%, all P<0.01], but they were higher than normal levels.Conclusion DSM has the effect of inhibiting the activation of vascular endothelial cells and platelet.The medicine may be used to prevent thrombotic diseases.
